ChiCTR2000031597 版本V1.3 版本创建时间2020/04/05 05:48:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000031597 

最近更新日期:

Date of Last Refreshed on:

2020-04-05 05:46:43 

注册时间:

Date of Registration:

2020-04-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

BRAF基因检测在乳头状颅咽管瘤早期诊断中的作用研究

Public title:

The role of BRAF gene detection in the early diagnosis of papillary craniopharyngioma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

BRAF基因检测在乳头状颅咽管瘤早期诊断中的作用研究

Scientific title:

The role of BRAF gene detection in the early diagnosis of papillary craniopharyngioma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

冯英 

研究负责人:

冯英 

Applicant:

Feng Ying 

Study leader:

Feng Ying 

申请注册联系人电话:

Applicant telephone:

+86 13672106839

研究负责人电话:

Study leader's telephone:

+86 13672106839

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fyeagle@163.com

研究负责人电子邮件:

Study leader's E-mail:

fyeagle@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市光明区圳园路628号

研究负责人通讯地址:

广东省深圳市光明区圳园路628号

Applicant address:

628 Zhenyuan Road, Guangming District, Shenzhen, Guangdong, China

Study leader's address:

628 Zhenyuan Road, Guangming District, Shenzhen, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第七医院

Applicant's institution:

The Seventh Affiliated Hospital, Sun Yat-sen University

研究负责人所在单位:

中山大学附属第七医院

Affiliation of the Leader:

The Seventh Affiliated Hospital, Sun Yat-sen University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019SYSUSH-020

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第七医院科研和实验动物伦理委员会

Name of the ethic committee:

Research and experimental animal ethics committee of the seventh affiliated hospital of Sun Yat-sen University

伦理委员会批准日期:

Date of approved by ethic committee:

2019-10-25 00:00:00

伦理委员会联系人:

张薇

Contact Name of the ethic committee:

Zhang Wei

伦理委员会联系地址:

广东省深圳市光明区圳园路628号

Contact Address of the ethic committee:

628 Zhenyuan Road, Guangming District, Shenzhen, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学附属第七医院

Primary sponsor:

The Seventh Affiliated Hospital, Sun Yat-sen University

研究实施负责(组长)单位地址:

广东省深圳市光明区圳园路628号

Primary sponsor's address:

628 Zhenyuan Road, Guangming District, Shenzhen, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

深圳市

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

中山大学附属第七医院

具体地址:

广东省深圳市光明区圳园路628号

Institution
hospital:

The Seventh Affiliated Hospital, Sun Yat-sen University

Address:

628 Zhenyuan Road, Guangming District

经费或物资来源:

深圳市科创委自由探索项目

Source(s) of funding:

Shenzhen Science and technology innovation commission free exploration project

Target disease:

Craniopharyngioma

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

通过基因测序方法分析乳头状颅咽管瘤患者手术前外周血和术后肿瘤组织的BRAF V600E基因突变检测阳性率的一致性,为乳头状颅咽管瘤的早期诊断提供一种新的方法。  

Objectives of Study:

The gene sequencing method was used to analyze the consistency of BRAF V600E gene mutation detection in peripheral blood and postoperative tumor tissues of patients with papillary choroidal tumor, which provided a new method for early diagnosis of papillary craniopharyngioma.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)患者年龄在1岁至75岁之间,性别不限;
(2)手术后病理诊断证实为乳头状颅咽管瘤的患者;
(3)患者无其他部位肿瘤,尤其是甲状腺乳头状癌、肺小细胞癌、黑色素瘤等;
(4)女性患者非妊娠期及哺乳期;
(5)心肺功能正常。

Inclusion criteria

(1) Patient aged 1 and 75 years;
(2) Patients with papillary craniopharyngioma confirmed by pathological diagnosis after surgery;
(3) The patient has no other tumors, especially papillary thyroid carcinoma, small cell lung cancer, melanoma, etc.;
(4) Female patients are not pregnant and lactating;
(5) Cardiopulmonary function is normal.

排除标准:

(1)鞍区其他性质的病变(如:垂体瘤/生殖细胞瘤/炎症/肉芽肿等);
(2)鞍区占位病变已行手术,但术后无病理学诊断;
(3)患者合并其他部位肿瘤;
(4)妊娠或哺乳期的女性患者;
(5)明显心血管功能异常,或严重肺部疾患者。

Exclusion criteria:

(1) Other lesions in the sellar region (eg pituitary tumor / germ cell tumor / inflammation / granuloma, etc.);
(2) Surgery has been performed in the saddle area lesion, but no pathological diagnosis after operation;
(3) The patient has a tumor in another part;
(4) Female patients during pregnancy or lactation;
(5) Patients with obvious cardiovascular dysfunction or severe pulmonary disease.

研究实施时间:

Study execute time:

From 2019-03-20 00:00:00 To 2022-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-04-03 00:00:00 To 2021-03-31 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

术后肿瘤组织的BRAF V600E基因突变检测

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Post surgery tumor tissue detection of BRAF V600E gene

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

术前外周血 BRAF V600E 基因检测

Index test:

Pre-surgery peripheral blood detection of BRAF V600E

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

乳头状颅咽管瘤的患者

例数:

Sample size:

30

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients with papillary craniopharyngioma

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

中山大学附属第七医院 

单位级别:

三级医院 

Institution
hospital:

The Seventh Affiliated Hospital, Sun Yat-sen University

Level of the institution:

Tertiary Hospital

测量指标:

Outcomes:

指标中文名:

BRAF基因

指标类型:

主要指标

Outcome:

BRAF gene

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肿瘤组织

组织:

颅脑

Sample Name:

Tumor tissue

Tissue:

Brain

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

外周血

组织:

Sample Name:

Peripheral blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 1 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

no

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-04-05 05:36:26